ARTICLE | Company News
FDA approves Novartis' Mayzent for MS
March 27, 2019 12:37 AM UTC
FDA's approval of Novartis’ Mayzent siponimod late Tuesday with a broad label could position the multiple sclerosis drug to stand out from a crowded field with its approval for secondary progressive MS, an indication for which there are few marketed therapies.
Nearly all MS patients eventually progress to SPMS. Mayzent is approved to treat adults with relapsing forms of multiple sclerosis, including SPMS with active disease, relapse-remitting MS (RRMS) and clinically isolated syndrome...